IPCA Laboratories Ltd

Ipca Laboratories will hold a board meeting on November 5, 2026, to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Ltd. and National Stock Exchange of India Limited. Trading in the company's securities will be closed for insiders from October 1, 2026, until November 7, 2026, following a prior announcement on September 22, 2026.

Ipca Laboratories Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange India Limited on October 12, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as certified by MUFG Intime India Private Limited, formerly Link Intime India Private Limited.

Ipca Laboratories Limited informed the BSE Ltd. and National Stock Exchange India Limited that the trading window for dealing in the company's securities will be closed from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the second quarter and half year ended September 30, 2026.

Ipca Laboratories Ltd share price ticked higher by 0.99% to Rs 1766.7 after the company's net profit saw a strong growth of 36.65% to Rs 422.81 crore, while revenue from operations gained 16.73% to Rs 2788.1 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.61%. It has improved by 0.97% over last one week and advanced by 11.17% in last one month while the market capitalization of Ipca Laboratories Ltd has inched up 1.92% and 10.02% in the same period respectively. Profit before tax (PBT) of Ipca Laboratories Ltd stood at Rs 572.08 crore in Q2 FY26, surging by 73.09% year-on-year, and jumping 41.45% quarter-on-quarter. EBITDA came in at Rs 644 crore, rallying 67.88% YoY and expanding by 65.14% sequentially. Total expenses rose by 10.82% to Rs 2229.4 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 638.14 crore, posting a minor increase of 7.68% YoY, while employee benefits expense was at Rs 601.56 crore, witnessing a strong rise of 12.86% YoY. For the TTM ended FY26, revenue from operations grew marginally by 7.91% to Rs 9646.33 crore, while net profit soared by 51.28% to Rs 1191.37 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 165264% to Rs 1804.11 crore, and PBT witnessed a strong rise of 39.02% to Rs 1572.52 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1141.97 crore in FY26, as against Rs 1321.32 crore in FY25. Ipca Laboratories Ltd rallied 28.37% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.

Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1815.1, up 2.75% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.26% on the day, quoting at 24372.4. The Sensex is at 77881.48, down 0.11%. Ipca Laboratories Ltd has dropped around 1.37% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has dropped around 2.8% in last one month and is currently quoting at 26762.5, down 0.49% on the day. The volume in the stock stood at 2.24 lakh shares today, compared to the daily average of 2.26 lakh shares in last one month.The PE of the stock is 39.45 based on TTM earnings ending March 26.

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 August 2026.

Ipca Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1879.3, up 2.11% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Ipca Laboratories Ltd has risen around 21.23% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 1.72 lakh shares today, compared to the daily average of 2.43 lakh shares in last one month.The PE of the stock is 40.42 based on TTM earnings ending March 26.Powered by Capital Market - Live

Ipca Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 13 August 2026.

Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1831.5, up 2.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 24216.7. The Sensex is at 77693.16, up 0.16%. Ipca Laboratories Ltd has risen around 16.23% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 5.67% in last one month and is currently quoting at 25674.1, down 0.32% on the day. The volume in the stock stood at 2.25 lakh shares today, compared to the daily average of 2.31 lakh shares in last one month.The PE of the stock is 39.27 based on TTM earnings ending March 26.Powered by Capital Market - Live

The board of Ipca Laboratories at its meeting held on 26 June 2026 has approved the scheme of amalgamation of Krebs Biochemicals & Industries (Transferor Company) with the company (Transferee Company) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.